L-NAME hydrochloride

A widely used inhibitor of NO synthase (NOS) with IC50 of 70 uM for purified brain NOS; inhibits cGMP formation in endothelial cells with an IC50 of 3.1 μM (in the presence of 30 μM arginine) and reverses the vasodilation effects of acetylcholine in rat aorta rings.Asthma Phase 3 Clinical (In Vitro) :L-arginine analogues are widely used inhibitors of nitric oxide synthase (NOS) activity, with Nw-nitro-L-arginine methyl ester (L-NAME) being at the head. Freshly dissolved L-NAME is a 50 fold less potent inhibitor of purified brain NOS (mean IC50= 70 μM) than L-NOARG (IC50= 1.4 μM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. HPLC analyses reveal that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG. (In Vivo) :L-NAME infusion significantly decreases NKT-leukocyte level, tumor-necrosis factor (TNF) -alpha production by T-splenocytes and macrophages, and IFNγ production by T-leukocytes, monocytes, and T-splenocytes, as well as increased interleukin-6 production by T-leukocytes and monocytes and nitrate/nitrite production by T-leukocytes. There is increasing evidence that nitric oxide may be involved in learning and memory. l-NAME produces a task-dependent impairment of fear extinction, and implies that nitric oxide signaling is involved in memory process of certain fear extinction tasks. Chronic L-NAME administration induces cardiac hypertrophy in rodent models. Six weeks L-NAME administration induces significant cardiac hypertrophy compared to control hearts.

51298-62-5

NG-Nitroarginine methyl ester hydrochloride

>98% (HPLC)

H2O: ≥ 32 mg/mL

COC (=O) [C@H] (CCCN=C (N) N[N+] (=O) [O-]) N.Cl

C7H16ClN5O4

269.686

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.